Calendario›REGN›Cemiplimab
Cemiplimab
Ensayo de REGENERON PHARMACEUTICALS, INC. en Cáncer de pulmón no microcítico.
Más ensayos de: Cáncer de pulmón no microcítico.
Todo sobre el fármaco: Cemiplimab.
- Fase
- Fase 2
- Estado
- En marcha, sin reclutar
- Participantes
- 184
- Centros
- 47
- Fin del objetivo primario
- dic 2029
Título oficial en el registro (en inglés): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en nov 2024.
De principio a fin
Desde que lo vigilamos, su lectura se ha retrasado 31 meses en total.
- Empieza el ensayo (nov 2024)
- Mueve la lectura: may 2027 → dic 2029 (+31 meses) · visto el 6 nov 2026
- Hoy
- Lectura de resultados dic 2029 (prevista)
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 6 nov 2026 | Lectura de resultados | may 2027 → dic 2029 |
Qué mide
Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR) (del registro, en inglés) (hasta 12 semanas)
Qué se prueba
Se incluye a adultos con cáncer de pulmón no microcítico en estadio II-IIIB para los que se prevé cirugía.
Lo que dice el documentoThis study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion. The aim of the resectable NSCLC portion is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. For each investigational arm, the available data will be reviewed to decide whether safety testing with chemotherapy is needed before moving the treatment combination to the main resectable NSCLC portion of the study. If safety testing with chemotherapy is required, adult participants whose tumour has spread to other organs or cannot be removed by surgery, will be enrolled in the unresectable/metastatic NSCLC portion of the study called the "safety lead-in." The aim of the unresectable/metastatic NSCLC safety lead-in portion is to evaluate the safety of the combination of Cemiplimab, chemotherapy, and an additional drug in participants with unresectable or metastatic NSCLC. For the resectable NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed * How much of the study drug(s) are in the blood at a given time * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects) For the unresectable/metastatic NSCLC portion, the study is also looking at several other research questions, including: * What are the side effects associated with the additional drug in combination with cemiplimab and chemotherapy * How does the additional drug work in combination with cemiplimab and chemotherapy
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| cemiplimab | Fase 2 | En marcha, sin reclutar | mar 2025 (real) |
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06465329), actualizada en oct 2026.